Short antisense oligonucleotides alleviate the pleiotropic toxicity of RNA harboring expanded CGG repeats.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33627639.
- Also identified by DOI 10.1038/s41467-021-21021-w and PMC identifier 7904788.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Fragile X-associated tremor/ataxia syndrome (FXTAS) is an incurable neurodegenerative disorder caused by expansion of CGG repeats in the FMR1 5'UTR. The RNA containing expanded CGG repeats (rCGG<sup>exp</sup>) causes cell damage by interaction with complementary DNA, forming R-loop structures, sequestration of nuclear proteins involved in RNA metabolism and initiation of translation of polyglycine-containing protein (FMRpolyG), which forms nuclear insoluble inclusions. Here we show the therapeutic potential of short antisense oligonucleotide steric blockers (ASOs) targeting directly the rCGG<sup>exp</sup>. In nuclei of FXTAS cells ASOs affect R-loop formation and correct miRNA biogenesis and alternative splicing, indicating that nuclear proteins are released from toxic sequestration. In cytoplasm, ASOs significantly decrease the biosynthesis and accumulation of FMRpolyG. Delivery of ASO into a brain of FXTAS mouse model reduces formation of inclusions, improves motor behavior and corrects gene expression profile with marginal signs of toxicity after a few weeks from a treatment.
Medical subject headings
- Ataxia
- Fragile X Messenger Ribonucleoprotein 1
- Fragile X Syndrome
- Oligonucleotides, Antisense
- Tremor
- Trinucleotide Repeat Expansion